关于子公司产品获得三类医疗器械注册证的公告 证券代码：600587 证券简称：新华医疗 公告编号：临 2024-016 山东新华医疗器械股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 4、注册人住所：上海市松江区文翔路 419 号 5、生产地址：上海市松江区文翔路 419 号 6、结构及组成：可吸收外科缝线由缝线和缝合针（可选）组成，分带针型 （带单/双针）和不带针型。缝线材质为聚对二氧环己酮（PDO），单股、无涂 层；缝合针材质为 302 不锈钢，含硅涂层；缝线颜色为紫色，染料为 D&C 紫色二 号。产品经环氧乙烷灭菌，一次性使用。 7、适用范围：该产品适用于适合使用可吸收缝线的软组织缝合。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）子公 司上海天清生物材料有限公司于近日收到国家药品监督管理局颁发的《中华人民 共和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 1、产品名称：可吸收性外科缝线 2、注册证编号：国械注准 20243020865 3、注册人名称：上海天清生 ...

Financial Performance - Total revenue for Q1 2024 was CNY 2,528,538,840.43, representing a year-on-year increase of 3.68%[14] - Net profit attributable to shareholders for Q1 2024 was CNY 211,036,820.12, an increase of 7.39% compared to the same period last year[14] - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 208,965,933.49, reflecting a 13.77% increase year-on-year[14] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.45, a decrease of 2.17% compared to the previous year[14] - The weighted average return on equity was 2.87%, down by 0.45 percentage points from the previous year[14] - Net profit rose to ¥215,024,150.02, compared to ¥202,032,967.27, marking an increase of approximately 6.9%[48] - Total profit amounted to ¥240,004,730.67, up from ¥236,108,942.41, indicating a growth of about 1.9%[47] - The company’s total comprehensive income reached ¥215,024,150.02, compared to ¥202,032,967.27, reflecting an increase of about 6.4%[48] Assets and Liabilities - The total assets at the end of the reporting period were CNY 15,446,957,749.70, a decrease of 0.92% from the end of the previous year[11] - Total assets decreased from 15,590,329,775.23 to 15,446,957,749.70, a decline of approximately 0.92%[43] - Total liabilities decreased from 7,870,494,104.65 to 7,581,952,161.40, a decline of approximately 3.67%[44] - Total equity increased from 7,719,835,670.58 to 7,865,005,588.30, an increase of approximately 1.89%[45] Cash Flow - The net cash flow from operating activities for Q1 2024 was CNY -213,902,750.72, a significant decrease of 1,425.74% year-on-year[14] - Cash flow from operating activities in Q1 2024 was ¥2,244,699,365.87, compared to ¥2,677,674,550.70 in Q1 2023, indicating a decrease of 16.2%[37] - Cash flow from operating activities showed a net outflow of ¥213,902,750.72, contrasting with a net inflow of ¥16,134,620.03 in the previous period[50] - Investment activities resulted in a net cash outflow of ¥85,696,029.09, improving from a larger outflow of ¥139,927,754.81 previously[50] Expenses - Total operating costs for Q1 2024 were ¥2,298,905,534.93, up from ¥2,215,993,908.16 in Q1 2023, reflecting a year-over-year increase of 3.7%[33] - The company’s management expenses decreased to ¥88,190,919.48 in Q1 2024 from ¥113,528,277.78 in Q1 2023, a reduction of 22.3%[33] - Tax expenses for Q1 2024 were reported at ¥14,318,968.54, slightly down from ¥14,661,765.48 in Q1 2023[33] - R&D expenses increased to ¥83,305,119.71 from ¥73,557,725.07, reflecting a growth of approximately 13.7% year-over-year[47] - Financial expenses decreased significantly to ¥4,405,363.44 from ¥8,362,979.58, a reduction of about 47.3%[47] Investments and Other Financial Metrics - The company reported a significant increase in investment income to ¥18,623,683.78 from ¥11,029,530.70, a growth of approximately 68.5%[47] - The company reported a net profit of ¥0 from the merged entity prior to the merger, consistent with the previous period[36] - The company has not indicated any new product launches or technological developments during this reporting period[40] - There were no significant market expansions or acquisitions reported in the current quarter[40] Shareholder Information - The company has maintained a stable shareholder structure, with the largest shareholder holding 28.91% of the shares[26]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600587 证券简称：新华医疗 公告编号：临 2024-015 山东新华医疗器械股份有限公司 2023 年年度股东大会决议公告 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 107 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 169,713,451 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 36.3659 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长王玉全先生主持，会议采用现场投 (一) 股东大会召开的时间：2024 年 4 月 18 日 (二) 股东大会召开的地点：淄博市高新技术产业开发区泰美路 7 号新华医疗 科技园办公楼三楼会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 票与网络投票相结合的方式表决， ...

北京市东城 区北三环东 路36号环球 贸易中心 B 座 11 层 电话（Tel）： 52213236/7 邮编（P.C）： 100013 北京市君致律师事务所 关于山东新华医疗器械股份有限公司 北京市君致律师事务所（以下简称"本所"）受山东新华医疗器械股份有限公 司（以下简称"公司"）的委托，指派律师出席 2024 年 4 月 18 日上午 9:00 点召 开的公司 2023 年度股东大会（以下简称"本次股东大会"）；依据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）、《上市公司股东大会规则》（以下简称"《股东大会规则》"）等现行法 律、法规和其他规范性文件及《山东新华医疗器械股份有限公司章程》的规定， 特就公司本次股东大会相关事宜，出具本法律意见书。 致：山东新华医疗器械股份有限公司 2023 年度股东大会的法律意见书 对本法律意见书的出具，本所特作如下声明： 1、本所及经办律师依据《证券法》、《律师事务所从事证券法律业务管理办 法》和《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前 已经发生或者存在的事实，严格履行了法定职责，遵循 ...

Investment Rating - The report maintains an "Outperform" rating for the company [1] Core Views - The company's main business gross margin has improved, with a focus on medical devices and pharmaceutical equipment manufacturing, which accounted for 61.5% of the main business revenue in 2023, up 2.5 percentage points year-on-year [4] - The company's international business achieved a breakthrough, with revenue reaching 241 million yuan in 2023, a 55.36% increase year-on-year, and the gross margin of international business is significantly higher than that of domestic business [4] - The company continues to divest inefficient and non-performing assets, further focusing its business [4] - The pharmaceutical equipment segment achieved revenue of 1.923 billion yuan in 2023, a 26.73% year-on-year increase, with significant growth in international contracts [5] - The medical devices segment achieved revenue of 4.167 billion yuan in 2023, a 9.15% year-on-year increase, with key progress in national-level R&D projects and breakthroughs in the biosafety market [17] Financial Performance - The company achieved revenue of 10.012 billion yuan in 2023, a 7.87% year-on-year increase, with net profit attributable to the parent company of 654 million yuan, a 30.78% year-on-year increase [16] - The gross margin in 2023 was 27.37%, up 0.93 percentage points year-on-year [4] - The company's net profit is expected to grow by 25.0%, 19.4%, and 15.1% year-on-year from 2024 to 2026, reaching 818 million yuan, 976 million yuan, and 1.124 billion yuan, respectively [18] - The company's revenue is expected to grow by 8.1%, 7.7%, and 7.7% year-on-year from 2024 to 2026, reaching 10.821 billion yuan, 11.655 billion yuan, and 12.549 billion yuan, respectively [19] Market Performance - The company's stock price has shown significant fluctuations, with a 52-week range of 17.12 to 36.95 yuan [14] - The company's total market capitalization is 10.734 billion yuan, with a circulating market capitalization of 10.238 billion yuan [14] Industry and Competitive Landscape - The company is expected to benefit from the new infrastructure in the pharmaceutical industry and the incremental demand in the pharmaceutical equipment sector, with rapid development in both medical devices and pharmaceutical equipment segments [18] - The company's product upgrades and structural optimization are expected to further enhance profitability [18] Financial Projections - The company's EPS is expected to be 1.75 yuan, 2.09 yuan, and 2.41 yuan in 2024, 2025, and 2026, respectively [19] - The company's gross margin is expected to be 27.6%, 28.1%, and 28.7% in 2024, 2025, and 2026, respectively [19] - The company's ROE is expected to be 10.1%, 10.9%, and 11.3% in 2024, 2025, and 2026, respectively [19]

山东新华医疗器械股份有限公司 2023 年年度股东大会资料 二О二四年三月二十七日 新华医疗 2023 年年度股东大会 山东新华医疗器械股份有限公司 2023 年年度股东大会会议议程 现场会议时间：2024 年 4 月 18 日（周四）上午 9:00 现场会议地点：公司办公楼三楼会议室 现场会议地址：山东省淄博市高新技术产业开发区泰美路 7 号新华医疗科技园 现场会议议程： 1、选举监票人 ； 2、审议《2023 年年度报告全文及摘要》； 3、审议《2023 年度董事会工作报告》； 4、审议《2023 年度监事会工作报告》； 5、审议《2023 年度财务决算报告及 2024 年度财务预算报告》； 6、审议《2023 年度利润分配预案》； 7、审议《2023 年度独立董事述职报告》； 8、审议《关于续聘天职国际会计师事务所（特殊普通合伙）为公司 2024 年度财 务审计机构和内部控制审计机构的议案》； 9、审议《关于对外担保的议案》； 10、审议《关于向银行申请综合授信额度并予以相应授权的议案》； 11、审议《关于修订<独立董事工作制度>的议案》； 12、审议《公司未来三年分红回报规划(2024-2026 年) ...

证券代码：600587 证券简称：新华医疗 公告编号：临 2024-014 山东新华医疗器械股份有限公司 关于召开 2023 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 4 月 12 日(星期五) 至 4 月 18 日(星期四)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 shinva@163.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 山东新华医疗器械股份有限公司（以下简称"公司"）已于 2024 年 3 月 29 日发布公司 2023 年年度报告，为便于广大投资者更全面深入地了解公司 2023 年度经营成果、财务状况，公司计划于 2024 年 4 月 19 日上午 09:00-10:00 举行 2023 年度业绩暨现金分红说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以 ...

Investment Rating - The report assigns a "Hold" rating for the company, indicating that the stock is expected to perform in line with the market over the next six months [17]. Core Insights - The company achieved a total revenue of 10.01 billion yuan in 2023, representing a year-on-year increase of 7.9%. The net profit attributable to shareholders was 650 million yuan, up 30.8% year-on-year [2][4]. - The company has increased its R&D investment, with R&D expenses reaching 443 million yuan in 2023. It applied for 419 patents, including 87 invention patents, and was recognized as a national intellectual property advantage enterprise [3]. - The international business segment saw significant growth, with revenue from international operations reaching 24.13 million yuan, a 55.36% increase compared to the previous year [3]. Financial Performance - The company's gross profit margin improved to 27.4% in 2023, an increase of 1.1 percentage points year-on-year. The gross profit margin for medical device manufacturing products was 40.82%, while for pharmaceutical equipment, it was 27.12% [6]. - The company’s revenue from medical device manufacturing reached 4.167 billion yuan, a year-on-year increase of 9.15%, with surgical instruments and experimental technology products growing by 14.47% and 28.7%, respectively [23]. - The pharmaceutical equipment segment generated 1.923 billion yuan in revenue, reflecting a year-on-year growth of 26.73% [23]. Future Projections - The company is expected to see its net profit attributable to shareholders reach 850 million yuan, 1.09 billion yuan, and 1.31 billion yuan in 2024, 2025, and 2026, respectively, with corresponding PE ratios of 13, 10, and 8 [24]. - The report anticipates that the gross profit margin for medical device manufacturing will continue to rise, reaching 43%, 44%, and 45% over the next three years [11][28].

Investment Rating - The report maintains a "Buy" rating for the company [14]. Core Views - The company reported a total revenue of 10.01 billion yuan in 2023, representing a year-on-year growth of 7.87%, and a net profit attributable to shareholders of 654 million yuan, which is a 30.78% increase year-on-year [1][2]. - The company has seen a continuous optimization of its revenue structure, with a significant increase in international sales, which reached 241 million yuan, up 55.36% year-on-year [3]. - The company is focusing on R&D investments, with 443 million yuan spent in 2023, reflecting a 0.49% increase year-on-year, and is advancing several key projects in medical equipment [3][13]. Summary by Sections Financial Performance - In 2023, the company achieved a revenue of 10.01 billion yuan, with a net profit of 654 million yuan and a non-recurring net profit of 619 million yuan, marking increases of 30.78% and 23.20% respectively [1][2]. - The fourth quarter of 2023 saw a revenue of 2.695 billion yuan, a 2.42% increase year-on-year, but a decline in net profit to 75 million yuan, down 5.99% year-on-year, primarily due to asset impairment losses [2]. Revenue Structure - The company’s revenue from medical device manufacturing was 4.167 billion yuan, up 9.15% year-on-year, with a gross margin of 40.82% [13]. - The pharmaceutical equipment segment generated 1.923 billion yuan, reflecting a 26.73% increase year-on-year [13]. R&D and International Expansion - The company continues to invest in R&D, with a focus on innovative products such as the dual-mode high-speed continuous BFS products launched in September 2023 [3]. - The international business is growing rapidly, contributing 2.41% to total revenue with a gross margin of 50.94% [3]. Profitability and Valuation - The report projects a slight decrease in the 2024 net profit forecast to 816 million yuan, while increasing the 2025 forecast to 1.002 billion yuan [14]. - The current price corresponds to a price-to-earnings ratio (P/E) of 16 for 2023, with projections of 13 and 11 for 2024 and 2025 respectively [14].

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 32 yuan, compared to the current price of 22.86 yuan [12]. Core Views - The company has shown continuous improvement in its product structure and significant growth in international business, with a revenue increase of 7.87% year-on-year to 10.01 billion yuan in 2023 [12]. - The company's focus on its core business has led to a notable optimization of its revenue structure, with medical device revenue growing by 9.15% and pharmaceutical equipment revenue increasing by 26.73% [12]. - The international revenue has surged by 55.36% to 241 million yuan, with a gross margin of 50.94%, significantly higher than domestic margins [12]. - The company's gross margin improved to 27.37%, and the net profit margin increased from 5.42% in 2022 to 6.53% in 2023, indicating enhanced profitability [12]. Financial Summary - In 2023, total revenue was 10,012 million yuan, with a year-on-year growth of 7.9% expected to reach 11,143 million yuan in 2024 [2]. - The net profit attributable to the parent company was 654 million yuan in 2023, reflecting a growth of 30.1%, with projections of 833 million yuan in 2024 [2]. - Earnings per share (EPS) are forecasted to be 1.40 yuan in 2023, increasing to 1.78 yuan in 2024, with corresponding price-to-earnings (P/E) ratios of 16 and 13 respectively [2]. - The company’s total assets are projected to grow from 15,590 million yuan in 2023 to 20,677 million yuan by 2026 [15].